nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0422	0.126	CbGbCtD
Orlistat—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0396	0.119	CbGbCtD
Orlistat—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0396	0.119	CbGbCtD
Orlistat—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0359	0.107	CbGbCtD
Orlistat—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0359	0.107	CbGbCtD
Orlistat—LIPF—Triacylglyceride Synthesis—AGPS—acquired immunodeficiency syndrome	0.031	0.332	CbGpPWpGaD
Orlistat—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.031	0.0925	CbGbCtD
Orlistat—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.03	0.0898	CbGbCtD
Orlistat—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0272	0.0812	CbGbCtD
Orlistat—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0272	0.0812	CbGbCtD
Orlistat—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0261	0.0779	CbGbCtD
Orlistat—PLA2G7—Peptide hormone metabolism—ENPEP—acquired immunodeficiency syndrome	0.0136	0.146	CbGpPWpGaD
Orlistat—PLA2G7—blood plasma—acquired immunodeficiency syndrome	0.0106	0.0623	CbGeAlD
Orlistat—LIPF—digestive system—acquired immunodeficiency syndrome	0.0101	0.0593	CbGeAlD
Orlistat—PNLIP—blood plasma—acquired immunodeficiency syndrome	0.00929	0.0548	CbGeAlD
Orlistat—DAGLA—blood—acquired immunodeficiency syndrome	0.00618	0.0364	CbGeAlD
Orlistat—ABHD12—retina—acquired immunodeficiency syndrome	0.00509	0.03	CbGeAlD
Orlistat—DAGLA—nervous system—acquired immunodeficiency syndrome	0.00502	0.0296	CbGeAlD
Orlistat—DAGLA—central nervous system—acquired immunodeficiency syndrome	0.00483	0.0285	CbGeAlD
Orlistat—DAGLB—lung—acquired immunodeficiency syndrome	0.0042	0.0248	CbGeAlD
Orlistat—PLA2G7—lymphoid tissue—acquired immunodeficiency syndrome	0.00411	0.0242	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—IFNG—acquired immunodeficiency syndrome	0.00403	0.043	CbGpPWpGaD
Orlistat—PLA2G7—blood—acquired immunodeficiency syndrome	0.00387	0.0228	CbGeAlD
Orlistat—DAGLA—brain—acquired immunodeficiency syndrome	0.00384	0.0226	CbGeAlD
Orlistat—PLA2G4A—blood plasma—acquired immunodeficiency syndrome	0.00375	0.0221	CbGeAlD
Orlistat—PLA2G7—bone marrow—acquired immunodeficiency syndrome	0.00375	0.0221	CbGeAlD
Orlistat—PLA2G7—spinal cord—acquired immunodeficiency syndrome	0.00373	0.022	CbGeAlD
Orlistat—ABHD16A—blood—acquired immunodeficiency syndrome	0.00363	0.0214	CbGeAlD
Orlistat—PLA2G7—vagina—acquired immunodeficiency syndrome	0.00359	0.0211	CbGeAlD
Orlistat—PNLIP—digestive system—acquired immunodeficiency syndrome	0.00357	0.0211	CbGeAlD
Orlistat—ABHD16A—bone marrow—acquired immunodeficiency syndrome	0.00352	0.0207	CbGeAlD
Orlistat—ABHD16A—spinal cord—acquired immunodeficiency syndrome	0.0035	0.0206	CbGeAlD
Orlistat—PNLIP—blood—acquired immunodeficiency syndrome	0.0034	0.0201	CbGeAlD
Orlistat—ABHD12—blood—acquired immunodeficiency syndrome	0.0034	0.0201	CbGeAlD
Orlistat—PLA2G7—lung—acquired immunodeficiency syndrome	0.00339	0.02	CbGeAlD
Orlistat—ABHD16A—vagina—acquired immunodeficiency syndrome	0.00337	0.0198	CbGeAlD
Orlistat—ABHD12—spinal cord—acquired immunodeficiency syndrome	0.00328	0.0193	CbGeAlD
Orlistat—ABHD16A—lung—acquired immunodeficiency syndrome	0.00318	0.0188	CbGeAlD
Orlistat—ABHD12—vagina—acquired immunodeficiency syndrome	0.00316	0.0186	CbGeAlD
Orlistat—ABHD12—lung—acquired immunodeficiency syndrome	0.00298	0.0176	CbGeAlD
Orlistat—PNLIP—lung—acquired immunodeficiency syndrome	0.00298	0.0176	CbGeAlD
Orlistat—DAGLB—brain—acquired immunodeficiency syndrome	0.00297	0.0175	CbGeAlD
Orlistat—DAGLB—lymph node—acquired immunodeficiency syndrome	0.00287	0.0169	CbGeAlD
Orlistat—FASN—blood—acquired immunodeficiency syndrome	0.00286	0.0168	CbGeAlD
Orlistat—FASN—spinal cord—acquired immunodeficiency syndrome	0.00275	0.0162	CbGeAlD
Orlistat—FASN—vagina—acquired immunodeficiency syndrome	0.00265	0.0156	CbGeAlD
Orlistat—PLA2G7—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	0.00257	0.0275	CbGpPWpGaD
Orlistat—FASN—lung—acquired immunodeficiency syndrome	0.0025	0.0148	CbGeAlD
Orlistat—PLA2G7—brain—acquired immunodeficiency syndrome	0.0024	0.0142	CbGeAlD
Orlistat—PLA2G7—lymph node—acquired immunodeficiency syndrome	0.00232	0.0137	CbGeAlD
Orlistat—ABHD16A—lymph node—acquired immunodeficiency syndrome	0.00218	0.0128	CbGeAlD
Orlistat—ABHD12—brain—acquired immunodeficiency syndrome	0.00211	0.0124	CbGeAlD
Orlistat—ABHD12—lymph node—acquired immunodeficiency syndrome	0.00204	0.012	CbGeAlD
Orlistat—FASN—brain—acquired immunodeficiency syndrome	0.00177	0.0104	CbGeAlD
Orlistat—FASN—lymph node—acquired immunodeficiency syndrome	0.00171	0.0101	CbGeAlD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—ALB—acquired immunodeficiency syndrome	0.00154	0.0165	CbGpPWpGaD
Orlistat—PLA2G4A—blood—acquired immunodeficiency syndrome	0.00137	0.00809	CbGeAlD
Orlistat—PLA2G4A—bone marrow—acquired immunodeficiency syndrome	0.00133	0.00783	CbGeAlD
Orlistat—PLA2G4A—spinal cord—acquired immunodeficiency syndrome	0.00132	0.0078	CbGeAlD
Orlistat—PLA2G4A—vagina—acquired immunodeficiency syndrome	0.00127	0.0075	CbGeAlD
Orlistat—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00124	0.00729	CbGeAlD
Orlistat—PLA2G4A—lung—acquired immunodeficiency syndrome	0.0012	0.00709	CbGeAlD
Orlistat—PLA2G4A—nervous system—acquired immunodeficiency syndrome	0.00111	0.00657	CbGeAlD
Orlistat—DAGLA—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00108	0.0115	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00108	0.0115	CbGpPWpGaD
Orlistat—PLA2G4A—central nervous system—acquired immunodeficiency syndrome	0.00107	0.00632	CbGeAlD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.00107	0.0115	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.000869	0.00928	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.000869	0.00928	CbGpPWpGaD
Orlistat—PLA2G4A—brain—acquired immunodeficiency syndrome	0.000852	0.00502	CbGeAlD
Orlistat—PLA2G4A—lymph node—acquired immunodeficiency syndrome	0.000823	0.00485	CbGeAlD
Orlistat—FASN—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000759	0.00811	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000653	0.00697	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000653	0.00697	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000636	0.0068	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000636	0.0068	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00059	0.00631	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00059	0.00631	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000572	0.00611	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000572	0.00611	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000566	0.00605	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000566	0.00605	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TAT—acquired immunodeficiency syndrome	0.000562	0.00601	CbGpPWpGaD
Orlistat—PNLIP—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000537	0.00573	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000527	0.00564	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000478	0.00511	CbGpPWpGaD
Orlistat—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000475	0.0028	CbGeAlD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000459	0.0049	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000459	0.0049	CbGpPWpGaD
Orlistat—PNLIP—Disease—CCNT1—acquired immunodeficiency syndrome	0.000456	0.00488	CbGpPWpGaD
Orlistat—CYP3A4—blood—acquired immunodeficiency syndrome	0.000453	0.00267	CbGeAlD
Orlistat—DAGLB—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000448	0.00478	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000448	0.00478	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000403	0.00431	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000403	0.00431	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000402	0.00429	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000402	0.00429	CbGpPWpGaD
Orlistat—FASN—Metabolism—TAT—acquired immunodeficiency syndrome	0.000398	0.00425	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000386	0.00412	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000386	0.00412	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000386	0.00412	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000386	0.00412	CbGpPWpGaD
Orlistat—FASN—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.00038	0.00406	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000378	0.00403	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000378	0.00403	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000378	0.00403	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000378	0.00403	CbGpPWpGaD
Orlistat—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000368	0.00217	CbGeAlD
Orlistat—DAGLB—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000365	0.0039	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000365	0.0039	CbGpPWpGaD
Orlistat—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000354	0.00209	CbGeAlD
Orlistat—DAGLB—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000349	0.00373	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000349	0.00373	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000343	0.00366	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000343	0.00366	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000343	0.00366	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000343	0.00366	CbGpPWpGaD
Orlistat—FASN—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000338	0.00361	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000326	0.00348	CbGpPWpGaD
Orlistat—FASN—Disease—CCNT1—acquired immunodeficiency syndrome	0.000323	0.00345	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000319	0.00341	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000319	0.00341	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000292	0.00312	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000292	0.00312	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000289	0.00309	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000287	0.00307	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000287	0.00307	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000283	0.00302	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000283	0.00302	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000276	0.00295	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000276	0.00295	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000271	0.0029	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000261	0.00279	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000261	0.00279	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000259	0.00277	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000259	0.00277	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000257	0.00275	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000257	0.00275	CbGpPWpGaD
Orlistat—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000255	0.000634	CcSEcCtD
Orlistat—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000254	0.000633	CcSEcCtD
Orlistat—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.000254	0.00063	CcSEcCtD
Orlistat—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000253	0.00063	CcSEcCtD
Orlistat—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.00063	CcSEcCtD
Orlistat—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000253	0.000628	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000253	0.000628	CcSEcCtD
Orlistat—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000252	0.000627	CcSEcCtD
Orlistat—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000251	0.000625	CcSEcCtD
Orlistat—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000251	0.000624	CcSEcCtD
Orlistat—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.000624	CcSEcCtD
Orlistat—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000251	0.000623	CcSEcCtD
Orlistat—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.000623	CcSEcCtD
Orlistat—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000251	0.000623	CcSEcCtD
Orlistat—Rash—Didanosine—acquired immunodeficiency syndrome	0.000249	0.000619	CcSEcCtD
Orlistat—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000249	0.000619	CcSEcCtD
Orlistat—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000249	0.000619	CcSEcCtD
Orlistat—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000249	0.000619	CcSEcCtD
Orlistat—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000249	0.000619	CcSEcCtD
Orlistat—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000248	0.000616	CcSEcCtD
Orlistat—Headache—Didanosine—acquired immunodeficiency syndrome	0.000247	0.000615	CcSEcCtD
Orlistat—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000247	0.000614	CcSEcCtD
Orlistat—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.000613	CcSEcCtD
Orlistat—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000246	0.000612	CcSEcCtD
Orlistat—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.000612	CcSEcCtD
Orlistat—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000246	0.000611	CcSEcCtD
Orlistat—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000245	0.00061	CcSEcCtD
Orlistat—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000244	0.000607	CcSEcCtD
Orlistat—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000244	0.000606	CcSEcCtD
Orlistat—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000243	0.000605	CcSEcCtD
Orlistat—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000243	0.000605	CcSEcCtD
Orlistat—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000243	0.000604	CcSEcCtD
Orlistat—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000243	0.000603	CcSEcCtD
Orlistat—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000242	0.000603	CcSEcCtD
Orlistat—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.000602	CcSEcCtD
Orlistat—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000242	0.000601	CcSEcCtD
Orlistat—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000242	0.000601	CcSEcCtD
Orlistat—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000242	0.000601	CcSEcCtD
Orlistat—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000241	0.000599	CcSEcCtD
Orlistat—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.000599	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000597	CcSEcCtD
Orlistat—PNLIP—Disease—CXCR4—acquired immunodeficiency syndrome	0.00024	0.00256	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000239	0.000595	CcSEcCtD
Orlistat—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000239	0.000594	CcSEcCtD
Orlistat—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000239	0.000594	CcSEcCtD
Orlistat—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000239	0.000594	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000239	0.000593	CcSEcCtD
Orlistat—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.000593	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000238	0.00255	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000238	0.00255	CbGpPWpGaD
Orlistat—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000238	0.000592	CcSEcCtD
Orlistat—Pain—Indinavir—acquired immunodeficiency syndrome	0.000237	0.000589	CcSEcCtD
Orlistat—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.000589	CcSEcCtD
Orlistat—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000237	0.000589	CcSEcCtD
Orlistat—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000237	0.000589	CcSEcCtD
Orlistat—DAGLA—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000237	0.00253	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000237	0.00253	CbGpPWpGaD
Orlistat—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000588	CcSEcCtD
Orlistat—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000236	0.000586	CcSEcCtD
Orlistat—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000236	0.000586	CcSEcCtD
Orlistat—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000235	0.000585	CcSEcCtD
Orlistat—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000235	0.000585	CcSEcCtD
Orlistat—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000235	0.000585	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000235	0.00251	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000235	0.00251	CbGpPWpGaD
Orlistat—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000235	0.000583	CcSEcCtD
Orlistat—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000235	0.000583	CcSEcCtD
Orlistat—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000234	0.000582	CcSEcCtD
Orlistat—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.000578	CcSEcCtD
Orlistat—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.000578	CcSEcCtD
Orlistat—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.000576	CcSEcCtD
Orlistat—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.000576	CcSEcCtD
Orlistat—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000231	0.000575	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000574	CcSEcCtD
Orlistat—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000231	0.000573	CcSEcCtD
Orlistat—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00023	0.000572	CcSEcCtD
Orlistat—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000228	0.000568	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.000568	CcSEcCtD
Orlistat—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000228	0.000566	CcSEcCtD
Orlistat—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000228	0.000566	CcSEcCtD
Orlistat—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.000566	CcSEcCtD
Orlistat—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000227	0.000566	CcSEcCtD
Orlistat—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000565	CcSEcCtD
Orlistat—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000227	0.000564	CcSEcCtD
Orlistat—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000227	0.000564	CcSEcCtD
Orlistat—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.000564	CcSEcCtD
Orlistat—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.000562	CcSEcCtD
Orlistat—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.000562	CcSEcCtD
Orlistat—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000226	0.000561	CcSEcCtD
Orlistat—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.000561	CcSEcCtD
Orlistat—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000225	0.00056	CcSEcCtD
Orlistat—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000225	0.000559	CcSEcCtD
Orlistat—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.000557	CcSEcCtD
Orlistat—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.000557	CcSEcCtD
Orlistat—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000224	0.000557	CcSEcCtD
Orlistat—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000224	0.000556	CcSEcCtD
Orlistat—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000223	0.000555	CcSEcCtD
Orlistat—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.000555	CcSEcCtD
Orlistat—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000222	0.000553	CcSEcCtD
Orlistat—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.000552	CcSEcCtD
Orlistat—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.000552	CcSEcCtD
Orlistat—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000551	CcSEcCtD
Orlistat—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.00055	CcSEcCtD
Orlistat—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000221	0.000548	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00022	0.000548	CcSEcCtD
Orlistat—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00022	0.000548	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.00022	0.00235	CbGpPWpGaD
Orlistat—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000545	CcSEcCtD
Orlistat—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000219	0.000545	CcSEcCtD
Orlistat—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000219	0.000545	CcSEcCtD
Orlistat—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000544	CcSEcCtD
Orlistat—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000219	0.000544	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.000219	0.00234	CbGpPWpGaD
Orlistat—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000218	0.000542	CcSEcCtD
Orlistat—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000218	0.000542	CcSEcCtD
Orlistat—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.00054	CcSEcCtD
Orlistat—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000217	0.000539	CcSEcCtD
Orlistat—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000217	0.000539	CcSEcCtD
Orlistat—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000539	CcSEcCtD
Orlistat—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000538	CcSEcCtD
Orlistat—Rash—Stavudine—acquired immunodeficiency syndrome	0.000216	0.000538	CcSEcCtD
Orlistat—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000537	CcSEcCtD
Orlistat—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000216	0.000537	CcSEcCtD
Orlistat—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000216	0.000537	CcSEcCtD
Orlistat—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000216	0.000536	CcSEcCtD
Orlistat—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000215	0.000536	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000215	0.0023	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000215	0.0023	CbGpPWpGaD
Orlistat—Headache—Stavudine—acquired immunodeficiency syndrome	0.000215	0.000534	CcSEcCtD
Orlistat—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000215	0.000534	CcSEcCtD
Orlistat—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000533	CcSEcCtD
Orlistat—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.000532	CcSEcCtD
Orlistat—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000214	0.000532	CcSEcCtD
Orlistat—Rash—Abacavir—acquired immunodeficiency syndrome	0.000213	0.00053	CcSEcCtD
Orlistat—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000213	0.000529	CcSEcCtD
Orlistat—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.000529	CcSEcCtD
Orlistat—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.000529	CcSEcCtD
Orlistat—Headache—Abacavir—acquired immunodeficiency syndrome	0.000212	0.000526	CcSEcCtD
Orlistat—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000211	0.000526	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000211	0.000525	CcSEcCtD
Orlistat—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000211	0.000525	CcSEcCtD
Orlistat—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000211	0.000524	CcSEcCtD
Orlistat—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000521	CcSEcCtD
Orlistat—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.000519	CcSEcCtD
Orlistat—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000208	0.000517	CcSEcCtD
Orlistat—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000208	0.000517	CcSEcCtD
Orlistat—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000515	CcSEcCtD
Orlistat—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000515	CcSEcCtD
Orlistat—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000514	CcSEcCtD
Orlistat—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.000513	CcSEcCtD
Orlistat—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000511	CcSEcCtD
Orlistat—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000205	0.000509	CcSEcCtD
Orlistat—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000204	0.000508	CcSEcCtD
Orlistat—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000204	0.000508	CcSEcCtD
Orlistat—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000204	0.000507	CcSEcCtD
Orlistat—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000204	0.000507	CcSEcCtD
Orlistat—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000204	0.000506	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000505	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000203	0.00216	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000203	0.00216	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000203	0.00216	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000203	0.00216	CbGpPWpGaD
Orlistat—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.000502	CcSEcCtD
Orlistat—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000501	CcSEcCtD
Orlistat—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000201	0.000499	CcSEcCtD
Orlistat—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000498	CcSEcCtD
Orlistat—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000497	CcSEcCtD
Orlistat—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000497	CcSEcCtD
Orlistat—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000199	0.000495	CcSEcCtD
Orlistat—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000199	0.000494	CcSEcCtD
Orlistat—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.000493	CcSEcCtD
Orlistat—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000493	CcSEcCtD
Orlistat—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000493	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000197	0.00211	CbGpPWpGaD
Orlistat—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.00049	CcSEcCtD
Orlistat—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.000488	CcSEcCtD
Orlistat—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000196	0.000488	CcSEcCtD
Orlistat—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.000482	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000194	0.000482	CcSEcCtD
Orlistat—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000193	0.00048	CcSEcCtD
Orlistat—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000479	CcSEcCtD
Orlistat—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000478	CcSEcCtD
Orlistat—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000478	CcSEcCtD
Orlistat—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.000475	CcSEcCtD
Orlistat—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.000475	CcSEcCtD
Orlistat—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000474	CcSEcCtD
Orlistat—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00019	0.000472	CcSEcCtD
Orlistat—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000189	0.000471	CcSEcCtD
Orlistat—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.000471	CcSEcCtD
Orlistat—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.000467	CcSEcCtD
Orlistat—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000188	0.000467	CcSEcCtD
Orlistat—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.000467	CcSEcCtD
Orlistat—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.000466	CcSEcCtD
Orlistat—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000187	0.000464	CcSEcCtD
Orlistat—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.000461	CcSEcCtD
Orlistat—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.00046	CcSEcCtD
Orlistat—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000185	0.000459	CcSEcCtD
Orlistat—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.000458	CcSEcCtD
Orlistat—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.000457	CcSEcCtD
Orlistat—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000457	CcSEcCtD
Orlistat—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000456	CcSEcCtD
Orlistat—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000183	0.000456	CcSEcCtD
Orlistat—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000455	CcSEcCtD
Orlistat—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000455	CcSEcCtD
Orlistat—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000453	CcSEcCtD
Orlistat—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.000452	CcSEcCtD
Orlistat—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00018	0.000447	CcSEcCtD
Orlistat—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000179	0.000446	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000179	0.00191	CbGpPWpGaD
Orlistat—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.000441	CcSEcCtD
Orlistat—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000441	CcSEcCtD
Orlistat—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000177	0.00044	CcSEcCtD
Orlistat—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000438	CcSEcCtD
Orlistat—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000438	CcSEcCtD
Orlistat—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000176	0.000438	CcSEcCtD
Orlistat—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.000436	CcSEcCtD
Orlistat—Rash—Indinavir—acquired immunodeficiency syndrome	0.000175	0.000435	CcSEcCtD
Orlistat—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000175	0.000434	CcSEcCtD
Orlistat—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000433	CcSEcCtD
Orlistat—Headache—Indinavir—acquired immunodeficiency syndrome	0.000174	0.000432	CcSEcCtD
Orlistat—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000431	CcSEcCtD
Orlistat—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000171	0.000426	CcSEcCtD
Orlistat—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000171	0.000424	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—TAT—acquired immunodeficiency syndrome	0.000171	0.00182	CbGpPWpGaD
Orlistat—FASN—Disease—CXCR4—acquired immunodeficiency syndrome	0.00017	0.00181	CbGpPWpGaD
Orlistat—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.00042	CcSEcCtD
Orlistat—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000418	CcSEcCtD
Orlistat—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000418	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000168	0.00179	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000168	0.00179	CbGpPWpGaD
Orlistat—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000166	0.000414	CcSEcCtD
Orlistat—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.000413	CcSEcCtD
Orlistat—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000412	CcSEcCtD
Orlistat—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.000411	CcSEcCtD
Orlistat—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.00041	CcSEcCtD
Orlistat—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000165	0.000409	CcSEcCtD
Orlistat—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000164	0.000409	CcSEcCtD
Orlistat—PNLIP—Disease—CCR5—acquired immunodeficiency syndrome	0.000164	0.00176	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000164	0.00175	CbGpPWpGaD
Orlistat—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000164	0.000408	CcSEcCtD
Orlistat—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.000408	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00016	0.00171	CbGpPWpGaD
Orlistat—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000398	CcSEcCtD
Orlistat—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000396	CcSEcCtD
Orlistat—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000159	0.000394	CcSEcCtD
Orlistat—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.000393	CcSEcCtD
Orlistat—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.000392	CcSEcCtD
Orlistat—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000392	CcSEcCtD
Orlistat—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.00039	CcSEcCtD
Orlistat—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000157	0.00039	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000156	0.00166	CbGpPWpGaD
Orlistat—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000156	0.000387	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000154	0.00165	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000154	0.00165	CbGpPWpGaD
Orlistat—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000381	CcSEcCtD
Orlistat—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.00038	CcSEcCtD
Orlistat—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000153	0.000379	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000152	0.00162	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000152	0.00162	CbGpPWpGaD
Orlistat—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000374	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00015	0.0016	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00015	0.0016	CbGpPWpGaD
Orlistat—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000149	0.00037	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000149	0.00159	CbGpPWpGaD
Orlistat—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000367	CcSEcCtD
Orlistat—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000366	CcSEcCtD
Orlistat—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000363	CcSEcCtD
Orlistat—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000363	CcSEcCtD
Orlistat—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000146	0.000362	CcSEcCtD
Orlistat—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000145	0.000361	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000145	0.00155	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000144	0.00154	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000142	0.00152	CbGpPWpGaD
Orlistat—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000353	CcSEcCtD
Orlistat—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.00035	CcSEcCtD
Orlistat—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.00035	CcSEcCtD
Orlistat—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000349	CcSEcCtD
Orlistat—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000347	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000139	0.00148	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000139	0.00148	CbGpPWpGaD
Orlistat—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000342	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000136	0.00145	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000136	0.00145	CbGpPWpGaD
Orlistat—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000336	CcSEcCtD
Orlistat—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000334	CcSEcCtD
Orlistat—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000333	CcSEcCtD
Orlistat—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.000331	CcSEcCtD
Orlistat—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000329	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000128	0.00136	CbGpPWpGaD
Orlistat—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000314	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000126	0.00134	CbGpPWpGaD
Orlistat—FASN—Disease—CCR5—acquired immunodeficiency syndrome	0.000116	0.00124	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000115	0.00123	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000115	0.00123	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000113	0.0012	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—acquired immunodeficiency syndrome	0.000103	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000101	0.00108	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ALB—acquired immunodeficiency syndrome	9.8e-05	0.00105	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.7e-05	0.00104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.7e-05	0.00104	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	9.45e-05	0.00101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.17e-05	0.00098	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.77e-05	0.000937	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.63e-05	0.000922	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.63e-05	0.000922	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.02e-05	0.000857	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.02e-05	0.000857	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.98e-05	0.000853	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.98e-05	0.000853	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—acquired immunodeficiency syndrome	7.34e-05	0.000784	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—acquired immunodeficiency syndrome	7.3e-05	0.00078	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—acquired immunodeficiency syndrome	6.94e-05	0.000741	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.68e-05	0.000714	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.65e-05	0.00071	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.56e-05	0.000701	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.46e-05	0.000691	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.99e-05	0.00064	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—acquired immunodeficiency syndrome	5.95e-05	0.000636	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.91e-05	0.000632	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—acquired immunodeficiency syndrome	5.58e-05	0.000596	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.42e-05	0.000579	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.1e-05	0.000545	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.1e-05	0.000545	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.71e-05	0.000504	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.71e-05	0.000504	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4e-05	0.000427	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—acquired immunodeficiency syndrome	3.95e-05	0.000422	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.91e-05	0.000417	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.88e-05	0.000414	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.82e-05	0.000408	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.49e-05	0.000373	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.42e-05	0.000365	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.4e-05	0.000363	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—acquired immunodeficiency syndrome	2.98e-05	0.000318	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.02e-05	0.000216	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.01e-05	0.000215	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000127	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	6.97e-06	7.45e-05	CbGpPWpGaD
